Luke Gaughan
Overview
Explore the profile of Luke Gaughan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knutson T, Luo B, Kobilka A, Lyman J, Guo S, Munro S, et al.
Nat Commun
. 2024 Dec;
15(1):10648.
PMID: 39663356
Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant...
2.
Walker L, Duncan R, Adamson B, Kendall H, Brittain N, Luzzi S, et al.
Mol Cancer Res
. 2024 Sep;
22(12):1128-1142.
PMID: 39348093
Resistance to androgen receptor (AR)-targeted therapies represents a major challenge in prostate cancer. A key mechanism of treatment resistance in patients who progress to castration-resistant prostate cancer (CRPC) is the...
3.
Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt E, et al.
Commun Biol
. 2024 Mar;
7(1):276.
PMID: 38448753
Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and prostate to promote immune...
4.
Harris R, Heer M, Levasseur M, Cartwright T, Weston B, Mitchell J, et al.
Nat Commun
. 2023 Nov;
14(1):7243.
PMID: 37945563
Histone modifications influence the recruitment of reader proteins to chromosomes to regulate events including transcription and cell division. The idea of a histone code, where combinations of modifications specify unique...
5.
Adamson B, Brittain N, Walker L, Duncan R, Luzzi S, Rescigno P, et al.
J Clin Invest
. 2023 Sep;
133(22).
PMID: 37751307
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of...
6.
Buskin A, Scott E, Nelson R, Gaughan L, Robson C, Heer R, et al.
Oncogene
. 2023 Jul;
42(32):2417-2427.
PMID: 37438470
A key challenge in the clinical management and cause of treatment failure of prostate cancer (PCa) is its molecular, cellular and clinical heterogeneity. Modelling systems that fully recapitulate clinical diversity...
7.
Gaughan L, Logan I, Neal D, Robson C
Nucleic Acids Res
. 2021 Sep;
49(17):10203-10206.
PMID: 34469575
No abstract available.
8.
Martinez R, Salji M, Rushworth L, Ntala C, Blanco G, Hedley A, et al.
Cancer Res
. 2021 May;
81(13):3664-3678.
PMID: 33985973
Androgen deprivation therapy (ADT) is the standard of care for treatment of nonresectable prostate cancer. Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this...
9.
Blomme A, Ford C, Mui E, Patel R, Ntala C, Jamieson L, et al.
Nat Commun
. 2020 May;
11(1):2508.
PMID: 32427840
Despite the clinical success of Androgen Receptor (AR)-targeted therapies, reactivation of AR signalling remains the main driver of castration-resistant prostate cancer (CRPC) progression. In this study, we perform a comprehensive...
10.
Bainbridge A, Walker S, Smith J, Patterson K, Dutt A, Min Ng Y, et al.
Nucleic Acids Res
. 2020 Apr;
48(10):5366-5382.
PMID: 32324216
Resistance to androgen receptor (AR) targeting therapeutics in prostate cancer (PC) is a significant clinical problem. Mechanisms by which this is accomplished include AR amplification and expression of AR splice...